drug · antibody
patient view →odronextamab
Phase 3updated 2mo agoby $REGN REGENERON PHARMACEUTICALS, INC.🔗 ChEMBL
Phase 3community read0 votes
Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and follicular lymphoma and 3 investigational indications.
indications
indications
DLBCL
targets
B-lymphocyte antigen CD20T cell surface glycoprotein CD3
all catalysts(0)
nothing on the calendar yet
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that